Clinical trials: Respiratory Viral Infections
COVID-19 Infection
Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)
This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes the disease COVID-19. This may help to improve testing for COVID-19.
- Trial name
- END CoV-2 (NCT04513990)
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
COVID-19
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05925127)
- Testing
- NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg)
- Where
- 50 sites in United States
- Volunteers
- 994 people, healthy volunteers welcome
- Sponsor
- Novavax
Stress, Anxiety
Cereset Research Long-Term Healthcare Worker Study
Randomized, controlled study of long-term maintenance Cereset Research after an initial 4-session intervention bolus versus usual care control following an initial 4-session intervention bolus.
- Conditions
- Stress, Anxiety, Autonomic Dysregulation, Acoustic Stimulation
- Trial name
- LT-HW (NCT05994261)
- Testing
- Cereset Research
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Covid19
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome…
- Trial name
- NCT04345653
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Mindfulness, COVID-19
Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19
The COVID-19 outbreak is having an impact on the well-being of healthcare workers. Previous reports on pandemics show that such an impact may last beyond the time of the outbreak.
- Conditions
- Mindfulness, COVID-19, Healthcare Worker
- Trial name
- NCT04555005
- Testing
- Mindfulness based intervention
- Where
- Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Influenza A
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge
The purpose of this study is to assess the safety, tolerability, efficacy, and immunogenicity of an influenza A vaccine (vaccine: FP-01.1), as compared to placebo, in healthy volunteers following a dose of influenza A virus.
- Trial name
- NCT02071329
- Testing
- Vaccine FP-01.1, Virus Challenge
- Where
- United Kingdom
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Acute Respiratory Infection, Asthma Exacerbations
Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma Exacerbations
REMASK trial is a Trial within Cohort study (TwiCs), nested within the COVIDENCE UK longitudinal study. It has been designed to determine whether the offer of a free reusable, elastomeric face mask to adults with asthma and other…
- Trial name
- REMASK (NCT06885229)
- Testing
- FloMask - reuseable face mask
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Queen Mary University of London
COVID-19
A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
This is a phase 1 study in which healthy adult volunteers will receive BRII-196/BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
- Trial name
- NCT04691180
- Testing
- BRII-196 and BRII-198
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Influenza
ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses
Infants and young children do not respond as well as adults to the flu vaccines currently available in the UK. Fluad, is a different type of influenza vaccine that has been available in the European continent for the last decade…
- Trial name
- NCT01682369
- Testing
- TIV (Aggripal), ATIV (Fluad)
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
- Trial name
- NCT01990846
- Testing
- Flufirvitide 3
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Influenza
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT06574503
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Influenza
Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 18 to 64 years of age.
- Trial name
- NCT01008956
- Testing
- GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2.
- Trial name
- NCT06178991
- Testing
- Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine
- Where
- 106 sites in United States
- Volunteers
- 8,795 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19, Vitamin D
Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers
In a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with…
- Trial name
- COVID-19 (NCT04535791)
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Coordinación de Investigación en Salud, Mexico
COVID19
ABC Science Collaborative Registry Study
The ABC Registry is associated with Pro00107943 and provides a resource for collecting information on members of school communities both regionally in North and South Carolina, as well as nationally in the United States (U.S.)…
- Trial name
- NCT04781218
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Human
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an…
- Trial name
- NCT03314662
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
- Where
- 20 sites in United States
- Volunteers
- 1,778 people, healthy volunteers welcome
- Sponsor
- Seqirus
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
This is the first-in-human phase 1/2a trial of the inhaled administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631705
- Testing
- DZIF-10c
- Where
- 6 sites in Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Cologne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.